12th Jul 2005 15:06
SR Pharma plc ("SR Pharma" or "the Company")Ordinary Shares of 1p eachLondon 12 July 2005 - Following the completion of the acquisition, announcedyesterday, of approximately 96 per cent. of Atugen AG acquired through theissue of SR Pharma Ordinary Shares, the Company now announces that thefollowing shareholders have an interest in 3 per cent. or more of the enlargedissued share capital of the Company:Shareholder Number of shares Percentage of issued capital Apax Europe IV - A LP 12,306,993 26.35% MPM Asset Management 1998 LLC 3,440,959 7.37% Novartis Forschungsstiftung 2,962,505 6.34% Technologie-Beteilgungs-Gesellschaft 2,869,400 6.14% mbh Bank von Ernst & Cie 2,769,284 5.93% J L Stanford 2,169,000 4.64% G A W Rook 1,510,000 3.23% In addition, SR Pharma's Non-executive Director Jeremy Curnock Cook is adirector and a substantial shareholder of Bioscience Managers Limited whichholds 604,398 Ordinary Shares representing 1.30 per cent. of the Company'senlarged issued share capital.Further information:Melvyn DaviesCompany SecretarySR Pharma plcTel: 020 7307 1620 ENDSR PHARMA PLCRelated Shares:
SLN.L